Cargando…

The rationale for including immune checkpoint inhibition into multimodal primary treatment concepts of head and neck cancer

BACKGROUND: Treatment of locally advanced squamous cell carcinomas of the head and neck (SCCHN) remains unsatisfactory. Although the addition of concurrent radiochemotherapy (RCT) or the combination of radiotherapy with blockade of the epidermal growth factor receptor (EGFR) have improved outcomes o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tinhofer, Ingeborg, Budach, Volker, Jöhrens, Korinna, Keilholz, Ulrich
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6460729/ https://www.ncbi.nlm.nih.gov/pubmed/31093338 http://dx.doi.org/10.1186/s41199-016-0009-6

Ejemplares similares

Mutational load and mutational patterns in relation to age in head and neck cancer
por: Meucci, Stefano, et al.
Publicado: (2016)

Increased Growth-Inhibitory and Cytotoxic Activity of Arsenic Trioxide in Head and Neck Carcinoma Cells with Functional p53 Deficiency and Resistance to EGFR Blockade
por: Boyko-Fabian, Mariya, et al.
Publicado: (2014)

Methylation of RAD51B, XRCC3 and other homologous recombination genes is associated with expression of immune checkpoints and an inflammatory signature in squamous cell carcinoma of the head and neck, lung and cervix
por: Rieke, Damian T., et al.
Publicado: (2016)

Spheroid Culture of Head and Neck Cancer Cells Reveals an Important Role of EGFR Signalling in Anchorage Independent Survival
por: Braunholz, Diana, et al.
Publicado: (2016)

Next-generation sequencing: hype and hope for development of personalized radiation therapy?
por: Tinhofer, Ingeborg, et al.
Publicado: (2015)

Combination of copanlisib with cetuximab improves tumor response in cetuximab-resistant patient-derived xenografts of head and neck cancer
por: Klinghammer, Konrad, et al.
Publicado: (2020)

Primary Extracellular Matrix Enables Long-Term Cultivation of Human Tumor Oral Mucosa Models
por: Gronbach, Leonie, et al.
Publicado: (2020)

PET measured hypoxia and MRI parameters in re-irradiated head and neck squamous cell carcinomas: findings of a prospective pilot study
por: Rogasch, Julian, et al.
Publicado: (2021)

CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab
por: Niehr, Franziska, et al.
Publicado: (2015)

Preclinical models of head and neck squamous cell carcinoma for a basic understanding of cancer biology and its translation into efficient therapies
por: Tinhofer, Ingeborg, et al.
Publicado: (2020)

Prognostic Factors Predict Oncological Outcome in Older Patients With Head and Neck Cancer Undergoing Chemoradiation Treatment
por: Stromberger, Carmen, et al.
Publicado: (2021)

Negative enrichment by immunomagnetic nanobeads for unbiased characterization of circulating tumor cells from peripheral blood of cancer patients
por: Liu, Zhian, et al.
Publicado: (2011)

Immune Checkpoint Inhibition in Head and Neck Cancer
por: Forster, Martin David, et al.
Publicado: (2018)

Comparison of the composition of lymphocyte subpopulations in non-relapse and relapse patients with squamous cell carcinoma of the head and neck before, during radiochemotherapy and in the follow-up period: a multicenter prospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)
por: Niu, Minli, et al.
Publicado: (2021)

Multimodality imaging of head and neck cancer
por: King, A.D.
Publicado: (2007)

Multimodality imaging of paragangliomas of the head and neck
por: Thelen, Jarett, et al.
Publicado: (2019)

Radiotherapy Quality Assurance for Head and Neck Squamous Cell Carcinoma
por: Van Gestel, Dirk, et al.
Publicado: (2020)

The Challenge to the Pathologist of PD-L1 Expression in Tumor Cells of Non-Small-Cell Lung Cancer—An Overview
por: Jöhrens, Korinna, et al.
Publicado: (2021)

ERCC2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapy
por: Guberina, Maja, et al.
Publicado: (2020)

Correction: ERCC2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapy
por: Guberina, Maja, et al.
Publicado: (2020)

Implementation of Double Immune Checkpoint Blockade Increases Response Rate to Induction Chemotherapy in Head and Neck Cancer
por: Semrau, Sabine, et al.
Publicado: (2021)

Immune Checkpoints Pathways in Head and Neck Squamous Cell Carcinoma
por: Veigas, Florencia, et al.
Publicado: (2021)

Regional hyperthermia combined with chemotherapy in paediatric, adolescent and young adult patients: current and future perspectives
por: Seifert, Georg, et al.
Publicado: (2016)

Applicability of liquid biopsies to represent the mutational profile of tumor tissue from different cancer entities
por: Liebs, Sandra, et al.
Publicado: (2021)

Integrating Immunotherapy into Multimodal Treatment of Head and Neck Cancer
por: Rao, Yuan James, et al.
Publicado: (2023)

Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma
por: Mei, Zi, et al.
Publicado: (2020)

Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer
por: Sridharan, Vishwajith, et al.
Publicado: (2016)

Immune Checkpoint Inhibitor Toxicity in Head and Neck Cancer: From Identification to Management
por: Wang, Haiyang, et al.
Publicado: (2019)

Overcoming Resistance to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinomas
por: dos Santos, Lucas V., et al.
Publicado: (2021)

Rational Combinations of Targeted Therapy and Immune Checkpoint Inhibitors in Head and Neck Cancers
por: Chai, Annie Wai Yeeng, et al.
Publicado: (2022)

Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma
por: Oliva, M, et al.
Publicado: (2019)

Favorable therapeutic response after anti-Mesothelin antibody–drug conjugate treatment requires high expression of Mesothelin in tumor cells
por: Lazzerini, Lea, et al.
Publicado: (2020)

68Ga-PSMA-PET/CT-based radiosurgery and stereotactic body radiotherapy for oligometastatic prostate cancer
por: Kalinauskaite, Goda, et al.
Publicado: (2020)

SDF-1/CXCR4 expression in head and neck cancer and outcome after postoperative radiochemotherapy
por: De-Colle, Chiara, et al.
Publicado: (2017)

Prognostic factors for head and neck cancer of unknown primary including the impact of human papilloma virus infection
por: Axelsson, Lars, et al.
Publicado: (2017)

Combining Radiation and Immune Checkpoint Blockade in the Treatment of Head and Neck Squamous Cell Carcinoma
por: Manukian, Gregor, et al.
Publicado: (2019)

Prognostic value of immune checkpoint molecules in head and neck cancer: a meta-analysis
por: Jia, Yi-Qun, et al.
Publicado: (2019)

Current and Future Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma
por: Park, Jong Chul, et al.
Publicado: (2022)

Statin drugs enhance responses to immune checkpoint blockade in head and neck cancer models
por: Kansal, Vikash, et al.
Publicado: (2023)

Longitudinal and Multimodal Radiomics Models for Head and Neck Cancer Outcome Prediction
por: Starke, Sebastian, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_sdj8hgq876o9tae7629vrk7a6n